The prevalence of sarcoidosis-related cardiomyopathy is increasing. Sarcoidosis impacts
cardiac function through granulomatous infiltration of the heart, resulting in conduction …

Before becoming a cornerstone in the treatment of numerous immune-mediated diseases,
mycophenolate mofetil (MMF) was first introduced as an immunosuppressive agent in …

Background Although sex-and race-based patterns have been described in the extracardiac
organ involvement of sarcoidosis, cardiac sarcoidosis (CS)-specific studies are lacking …

Background Patients with suspected cardiac sarcoidosis frequently undergo
fluorodeoxyglucose (FDG)–positron emission tomography (PET)/computed tomography (CT) …

Cardiac sarcoidosis is an inflammatory myocardial disease of unknown etiology. It is
characterized by the deposition of non-caseating granulomas that may involve any part of …

Background Sarcoidosis is a systemic disease characterized by granulomatous
inflammation. Cardiac involvement is associated with increased morbidity. However …

Cardiac sarcoidosis is an infiltrative cardiomyopathy that results from granulomatous
inflammation of the myocardium and may present with high-grade conduction disease …

There are many challenging aspects of the management of cardiac sarcoidosis (CS) with
corticosteroids and other immunosuppressive therapy (IST). First, it is not always clear who …

Cardiac sarcoidosis (CS) is an increasingly recognized cause of heart failure and
arrhythmia. Historically challenging to identify, particularly in the absence of extracardiac …

Abstract Purpose of Review Cardiac sarcoidosis (CS) is an important cause of non-ischemic
cardiomyopathy and has specific diagnostic and therapeutic considerations. With advances …